文献速递胸部肿瘤

mTOR作为小细胞肺癌关键激酶的功能研究

Role of mTOR As an Essential Kinase in SCLC.
PubMed 文献 · J Thorac Oncol · 2020-06-26

该研究通过针对全部人类激酶的shRNA文库在7例初治小细胞肺癌患者来源异种移植瘤(PDX)中筛选生存相关激酶,发现mTOR在4例PDX中为关键激酶。mTOR磷酸化状态与PDX对mTOR激酶抑制的敏感性相关,mTOR抑制使PDX对顺铂和依托泊苷敏感化。在mTOR关键PDX中,mTOR抑制21天使肿瘤体积缩小43%(p<0.01),联合化疗70天较单纯化疗使肿瘤体积缩小96%(p<0.002),且105天内未出现化疗耐药。初治SCLC组织芯片中磷酸化mTOR-Ser-2448阳性率为27%。

要点

  • mTOR在部分SCLC PDX中为关键生存激酶,其磷酸化状态与mTOR抑制敏感性相关。
  • mTOR抑制联合顺铂和依托泊苷可显著缩小PDX肿瘤体积并防止化疗耐药。
  • 初治SCLC中磷酸化mTOR-Ser-2448阳性率为27%,可能界定可从mTOR抑制联合化疗获益的亚型。

核心结论

  • 激酶表达谱可区分SCLC亚组并识别治疗脆弱性,mTOR是部分SCLC的关键激酶和潜在治疗靶点。

研究设计与样本

  • 研究采用靶向全部人类激酶的shRNA文库,在7例初治SCLC患者来源异种移植瘤(PDX)中进行体外和体内筛选,丢失或耗竭的shRNA被认为调控细胞生存通路。

主要发现

  • 无监督层次聚类将7例PDX分为两个簇,提示SCLC PDX存在基于激酶的异质性。
  • 共23种激酶在2例或以上PDX中被鉴定为关键激酶,其中mTOR在4例PDX中为候选关键激酶。
  • mTOR磷酸化状态与PDX对mTOR激酶抑制的敏感性相关,mTOR抑制使PDX对顺铂和依托泊苷敏感化。
  • 在mTOR被定义为关键激酶的PDX中,mTOR抑制21天使肿瘤体积缩小43%(p<0.01)。
  • mTOR抑制联合顺铂和依托泊苷较单纯化疗在70天使PDX肿瘤体积缩小96%(p<0.002),且在105天内未出现化疗耐药。

临床怎么用

  • 磷酸化mTOR-Ser-2448阳性(27%)的初治SCLC亚型可能从标准化疗联合mTOR抑制中获益。

局限性

  • 研究基于7例PDX模型,样本量有限,结论需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SCLC represents 15% of all lung cancer diagnoses in the United States and has a particularly poor prognosis. We hypothesized that kinases regulating SCLC survival pathways represent therapeutically targetable vulnerabilities whose inhibition may improve SCLC outcome. METHODS: A short-hairpin RNA (shRNA) library targeting all human kinases was introduced in seven chemonaive patient-derived xenografts (PDX) and the cells were cultured in vitro and in vivo. On harvest, lost or depleted shRNAs were considered as regulating-cell survival pathways and deemed essential kinases. RESULTS: Unsupervised hierarchical cluster analysis of recovered shRNAs separated the PDXs into two clusters, suggesting kinase-based heterogeneity among the SCLC PDXs. A total of 23 kinases were identified as essential in two or more PDXs, with mechanistic Target of Rapamycin (mTOR) a candidate essential kinase in four. mTOR phosphorylation status correlated with PDX sensitivity to mTOR kinase inhibition, and mTOR inhibition sensitized the PDX to cisplatin and etoposide. In the PDX in which mTOR was defined as essential, mTOR inhibition caused a 43% decrease in tumor volume at 21 days (p < 0.01). Combining mTOR inhibition with cisplatin and etoposide decreased PDX tumor volume 96% compared with cisplatin and etoposide alone at 70 days (p < 0.002). Chemoresistance did not develop with the combination of mTOR inhibition and cisplatin and etoposide in mTOR-essential PDX over 105 days. The prevalence of phospho-mTOR-Ser-2448 in a tissue microarray of chemonaive SCLC was 27%, thus, identifying an important SCLC subtype that might benefit from the addition of mTOR inhibition to standard chemotherapy. CONCLUSIONS: These studies reveal that kinases can define SCLC subgroups, can identify therapeutic vulnerabilities, and can potentially be used to optimize therapeutic approaches. Significance We used functional genomics to identify kinases regulating SCLC survival. mTOR was identified as essential in a subset of PDXs. mTOR inhibition decreased PDX growth, sensitized PDX to cisplatin and etoposide, and prevented chemoresistance.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kern JA, Kim J, Foster DG, et al. Role of mTOR As an Essential Kinase in SCLC. J Thorac Oncol. 2020. PMID: 32599072. doi:10.1016/j.jtho.2020.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。